Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

ATCH vs ATYR: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ATCH Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 6–2 Matrix Metrics)

ATCH Overall Winner 6-Pillar Tally: ATCH 4 – 1 ATYR (1 Tie) Matrix Metrics: ATCH 6 – 2 ATYR

As of Nov 17, 2026, AtlasClear Holdings, Inc. (ATCH) is the stronger overall head-to-head candidate over aTyr Pharma, Inc. (ATYR) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ATCH carries a Unified Composite Score of 43.4/100 (HOLD) at $0.08 (N/M Forward P/E, -39.4% operating margin), whereas ATYR carries 34.3/100 (SELL) at $4.96 (N/M Forward P/E, 0.0% operating margin).

  • Technical & Structure Timing Caution: ATCH is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 18.0); meanwhile ATYR trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 57.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ATCH vs ATYR
ATCH NYSE American Head-to-Head Winner
AtlasClear Holdings, Inc.
Finance Services
$0.08
-37.17% 1D
Market Cap $20.1M
TTM Revenue $31M
Forward P/E N/M
Beta / 30D Vol 1.59β · 136% Vol
Unified Composite Score
43.4 / 100 HOLD
Tech 25.0 Fund 48.0 Flow 50.0 Mom 63.9
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -9.1%), weak momentum, RSI 18
RSI-14: 18.0 · SMA20: $0.15 · SMA50: $0.17
ATYR NASDAQ
aTyr Pharma, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$4.96
-5.34% 1D
Market Cap $15.6M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol -9.67β · 13806% Vol
Unified Composite Score
34.3 / 100 SELL
Tech 50.0 Fund 36.0 Flow 69.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (391.4% over 20 days), RSI 58
RSI-14: 57.6 · SMA20: $4.36 · SMA50: $1.92

6-Pillar Scorecard Institutional Category Breakdown (ATCH 4 – 1 ATYR)

Columns: Metric · ATCH · ATYR
1. Valuation Multiples ATCH
Forward P/E N/M N/M
Trailing P/E 6.6x N/M
PEG Ratio N/M N/M
EV / Revenue 0.6x N/M
2. Growth & Scale ATCH
Revenue Growth (YoY) +136.8% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $31M N/A
Market Cap $20.1M $15.6M
3. Profitability & Quality ATCH
Gross Margin 71.7% N/A
Operating Margin -39.4% 0.0%
Net Profit Margin 9.8% 0.0%
Return on Equity (ROE) 27.4% -93.7%
4. Balance Sheet & Cash Flow ATCH
Cash Generation (TTM) -$4.8M EBITDA N/A
Cash Flow Margin -15.5% EBITDA Mgn N/A
Net Cash / Leverage $2.3M Net Cash $4.9M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ATYR
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) 154.5% (36th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Capital Markets Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ATCH (6) vs ATYR (2)
Institutional Metric ATCH ATYR Criterion Row Edge
Market Capitalization
Scale
$20.1M $15.6M Larger Scale Tie
Trailing P/E Ratio
Valuation
6.6x N/M Lower Multiple ATCH
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+136.8% +0.0% Higher Growth ATCH
Operating Margin (TTM)
Profitability
-39.4% 0.0% Higher Margin ATYR
Net Profit Margin
Profitability
9.8% 0.0% Higher Margin ATCH
Return on Equity (ROE)
Capital Efficiency
27.4% -93.7% Higher ROE ATCH
52-Week Range Position
Momentum
4% ($0–$0) 62% ($0–$8) Stronger Trend ATYR
Beta / 30D Volatility
Risk Regime
1.59β · 136% Vol -9.67β · 13806% Vol Lower Realized Risk ATCH
Unified Institutional Score
Composite Signal
43.4 / 100 (HOLD) 34.3 / 100 (SELL) Higher Composite ATCH
Trailing 12M Revenue (USD)
Operating Scale
$31M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
71.7% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.6x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$4.8M EBITDA ($2.3M Net Cash) N/A ($4.9M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ATYR +3469.31 pp
ATCH: -49.76% · ATYR: +3419.55%
3M Horizon ATYR +1355.95 pp
ATCH: -56.73% · ATYR: +1299.22%
6M Horizon ATYR +1393.2 pp
ATCH: -67.32% · ATYR: +1325.88%
1Y Horizon ATYR +976.77 pp
ATCH: -72.79% · ATYR: +903.98%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period ATCH Revenue ATYR Revenue ATCH Op. Margin ATYR Op. Margin Margin Leader
FY2019 N/A $0M N/A -5445.0% ATYR
FY2020 N/A $10M N/A -152.2% ATYR
FY2022 N/A $10M N/A -446.8% ATYR
FY2023 N/A $0M N/A -15557.8% ATYR
FY2024 N/A $0M N/A -28899.6% ATYR
FY2025 $10M $0M -45.3% -40856.3% ATCH
FY2026 $20M N/A -48.7% N/A ATCH

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ATCH UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ATCH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ATYR UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 154.5%
IV Percentile 36th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact ATYR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ATCH Moat Profile Scale & Operating Efficiency Moat
Capital Markets Operator
Competes within the Capital Markets value chain with $20.1M market capitalization and -39.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ATYR Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $15.6M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ATCH vs ATYR Key Questions & Quantitative Answers

As of Nov 17, 2026, AtlasClear Holdings, Inc. (ATCH) is the stronger overall head-to-head candidate over aTyr Pharma, Inc. (ATYR) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ATCH carries a Unified Composite Score of 43.4/100 (HOLD) at $0.08 (N/M Forward P/E, -39.4% operating margin), whereas ATYR carries 34.3/100 (SELL) at $4.96 (N/M Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: ATCH is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 18.0); meanwhile ATYR trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 57.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ATCH leads the Growth & Scale pillar: ATCH posts +136.8% YoY revenue growth and +0.0% YoY earnings growth on $31M TTM revenue (71.7% gross margin, -39.4% operating margin), compared with ATYR at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). Across the 7-period historical trajectory (FY2019 to FY2026), ATCH cumulative revenue shifted +100.0% while ATYR shifted +0.0%. In operating R&D and SG&A reinvestment, ATCH deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ATYR.

ATCH screens cheaper on headline valuation multiples. ATCH trades at N/M Forward P/E, 6.6x Trailing P/E, N/M PEG, and 0.6x EV/Revenue (-15.5% EBITDA margin), whereas ATYR trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ATCH (27.4% ROE) versus ATYR (-93.7% ROE) capital efficiency.

In options market volatility and institutional positioning, ATCH carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.59β · 136% Vol realized risk). By comparison, ATYR carries 154.5% implied volatility (36th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-9.67β · 13806% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.